Haisco(SZ:002653) Quan Jing Wang·2025-12-23 01:55Core Viewpoint - Recently, Hisco (002653) received approval from the Shenzhen Stock Exchange's Listing Review Center for its application to issue shares to specific investors [1] Group 1: Share Issuance Details - Hisco plans to issue no more than 70 million shares, which does not exceed 30% of the total share capital prior to this issuance [4] - The total amount of funds to be raised from this issuance is capped at 1,245.2567 million yuan, which will be used for new drug research and development projects and to supplement working capital [4] Group 2: Fund Allocation - The investment amount for the new drug research project is 965.2567 million yuan, while 280 million yuan will be allocated to supplement working capital [5] - The total amount of funds raised will be 1,245.2567 million yuan [5] Group 3: Strategic Importance - The company is currently in a critical phase of transitioning to innovative drugs, maintaining a high level of R&D investment, with R&D expenditures as a percentage of revenue reaching 31.87%, 26.09%, and 26.90% for the years 2022 to 2024 respectively [6] - The company has seen a continuous expansion in market share for its key products, with innovative drugs such as the injection of环泊酚 (Sishuning), the capsule of苯磺酸克利加巴林 (Simeining), and others being included in the medical insurance directory [6] - The implementation of this fundraising project is expected to accelerate the R&D process of innovative drugs, expanding the depth and breadth of the company's product pipeline, thereby laying a solid foundation for the commercialization of more products [6]